losartan/aldesleukin (IMM-01) / Modulate Therap - LARVOL DELTA

DAAM2 Variants Cause Nephrotic Syndrome via Actin Dysregulation. (PubMed, Am J Hum Genet) - "Filopodia restoration was also induced by the formin-activating molecule IMM-01. We conclude that DAAM2 variants are a likely cause of monogenic human SRNS due to actin dysregulation in podocytes. Further, we provide evidence that DAAM2-associated SRNS may be amenable to treatment using actin regulating compounds."

Journal • Glomerulonephritis • Nephrology • Renal Disease

Phase update (clinicaltrials.gov) - Preclinical➔P1, Solid Tumor

Phase shift • Solid Tumor

Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Modulate Therapeutics Ltd

Checkpoint inhibition • Clinical • Monotherapy • New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Uveal Melanoma

Mutations in the Diaphanous Related Formin DAAM2 as a Novel Cause of Nephrotic Syndrome (KIDNEY WEEK 2019) - "Applying the formin activating small molecule IMM-01 caused filopodia formation in shRNA DAAM2-k.d. DAAM2 is likely a potential target for formin activating drugs. Funding NIDDK Support"